Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All deuremidevir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchDeuremidevirDeuremidevir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects

Qian et al., Acta Pharmacologica Sinica, doi:10.1038/s41401-022-00895-6, NCT05242042
Mar 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Phase 1 study of the safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog prodrug, in healthy subjects. A single ascending dose study, multiple ascending dose study, and food effect study were conducted sequentially in 86 subjects. VV116 exhibited dose-proportional pharmacokinetics up to 800mg and slight accumulation upon multiple twice daily dosing. Food intake prolonged time to peak levels but did not affect overall exposure.
Qian et al., 16 Mar 2022, placebo-controlled, China, peer-reviewed, 21 authors, study period November 2021 - January 2022, trial NCT05242042 (history). Contact: zhangwenhong@fudan.edu.cn, wangzhen@lglab.ac.cn, gyliu@shxh-centerlab.com.
This PaperDeuremidevirAll
Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects
Hong-Jie Qian, Yu Wang, Meng-Qi Zhang, Yuan-Chao Xie, Qing-Qing Wu, Li-Yu Liang, Ye Cao, Hua-Qing Duan, Guang-Hui Tian, Juan Ma, Zhuo-Bing Zhang, Ning Li, Jing-Ying Jia, Jing Zhang, Haji Akber Aisa, Jing-Shan Shen, Chen Yu, Hua-Liang Jiang, Wen-Hong Zhang, Zhen Wang, Gang-Yi Liu
Acta Pharmacologica Sinica, doi:10.1038/s41401-022-00895-6
VV116 (JT001) is an oral drug candidate of nucleoside analog against SARS-CoV-2. The purpose of the three phase I studies was to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of VV116 in healthy subjects, as well as the effect of food on the pharmacokinetics and safety of VV116. Three studies were launched sequentially: Study 1 (single ascending-dose study, SAD), Study 2 (multiple ascending-dose study, MAD), and Study 3 (food-effect study, FE). A total of 86 healthy subjects were enrolled in the studies. VV116 tablets or placebo were administered per protocol requirements. Blood samples were collected at the scheduled time points for pharmacokinetic analysis. 116-N1, the metabolite of VV116, was detected in plasma and calculated for the PK parameters. In SAD, AUC and C max increased in an approximately dose-proportional manner in the dose range of 25-800 mg. T 1/2 was within 4.80-6.95 h. In MAD, the accumulation ratio for C max and AUC indicated a slight accumulation upon repeated dosing of VV116. In FE, the standard meal had no effect on C max and AUC of VV116. No serious adverse event occurred in the studies, and no subject withdrew from the studies due to adverse events. Thus, VV116 exhibited satisfactory safety and tolerability in healthy subjects, which supports the continued investigation of VV116 in patients with COVID-19.
AUTHOR CONTRIBUTIONS All authors contributed to the studies and manuscript. GYL, ZW, WHZ, HLJ, CY, JSS, HAA, JZ, JYJ, HJQ, HQD, and GHT designed and supervised the study; HJQ, GYL, CY, JYJ, QQW, MQZ and LYL performed and executed the study; YW, ZW, JM, YCX, ZBZ, and NL analyzed and interpreted the data; HJQ, QQW, LYL, YCX, and YC wrote the initial draft; all authors critically reviewed or revised the draft of the manuscript, and approved the final manuscript. ADDITIONAL INFORMATION Competing interests: HQD and GHT are the employees of Vigonvita Life Science Co., Ltd, the sponsor of the study. JM, ZBZ, and NL are the employees of Shanghai Junshi Biosciences Co., Ltd., the parent company of the co-sponsor Shanghai JunTop Biosciences Co., Ltd. YCX, JSS, and HLJ filed a patent application on antiviral nucleoside analogs. The remaining authors declare no competing interests.
References
Agostini, Pruijssers, Chappell, Gribble, Lu et al., Smallmolecule antiviral β-d-N 4 -hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance, J Virol
Bernal, Da Silva, Musungaie, Kovalchuk, Gonzalez et al., Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients, N Engl J Med
Du, Yang, Zhang, Neutralizing antibodies for the prevention and treatment of COVID-19, Cell Mol Immunol
Fischer, Eron, Holman, Cohen, Fang et al., A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus, Sci Transl Med
Grein, Ohmagari, Shin, Diaz, Asperges et al., Compassionate use of remdesivir for patients with severe Covid-19, N Engl J Med
Kaabi, Zhang, Xia, Yang, Qahtani et al., Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial, J Am Med Assoc
Li, Wang, Lavrijsen, Lamers, De Vries et al., SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination, Cell Res, doi:10.1038/s41422-022-00618-w
Li, Yang, Quan, Li, Advancement of prodrug approaches for nucleotide antiviral agents, Curr Top Med Chem
Olender, Perez, Go, Balani, Eg et al., Remdesivir for severe coronavirus disease 2019 (COVID-19) versus a cohort receiving standard of care, Clin Infect Dis
Owen, Allerton, Anderson, Aschenbrenner, Avery et al., An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19, Science
Robson, Khan, Le, Paris, Demirbag et al., Coronavirus RNA proofreading: molecular basis and therapeutic targeting, Mol Cell
Rosenberg, Dorabawila, Easton, Bauer, Kumar et al., Covid-19 vaccine effectiveness in New York State, N Engl J Med
Seley-Radtke, Yates, The evolution of nucleoside analogue antivirals: a review for chemists and non-chemists. Part 1: early structural modifications to the nucleoside scaffold, Antivir Res
Spinello, Maria, Anna, Roberto, Gabriele, Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and non-ICU patients: clinical outcome and differences in posttreatment hospitalisation status, Pharmacol Res
Wang, Li, Dou, Shi, Duan et al., Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants, Emerg Microbes Infect
Xie, Yin, Zhang, Shang, Wang et al., Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2, Cell Res
Yates, Seley-Radtke, The evolution of antiviral nucleoside analogues: a review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold, Antivir Res
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit